Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement
Table 7
Estimated weighted-average per-exposure economic costs (in 2024 USD) and disease burdens (in DALYs) for dengue (where the circulating serotype is either the same as (DS) or different than (DD) that of any prior exposure) and Zika, based on regional prior exposure levels from [21,22], in the absence of dengue vaccination.